Nitric Oxide Synthase Inhibition Prevents Cell Proliferation in Glioblastoma

Daniel Kruglyakov; Shashank Kumar Ojha; Maryam Kartawy; Manish Kumar Tripathi; Wajeha Hamoudi; Wisam Bazbaz; Igor Khaliulin; Haitham Amal

doi:10.1007/s12031-023-02166-3

Nitric Oxide Synthase Inhibition Prevents Cell Proliferation in Glioblastoma

Daniel Kruglyakov, Shashank Kumar Ojha, Maryam Kartawy, Manish Kumar Tripathi, Wajeha Hamoudi, Wisam Bazbaz, Igor Khaliulin, Haitham Amal^*

^*Corresponding author for this work

School of Pharmacy

Research output: Contribution to journal › Article › peer-review

Abstract

Glioblastoma multiforme (GBM) is a prevalent and aggressive primary brain tumor, presenting substantial treatment challenges and high relapse rates. GBM is characterized by alterations in molecular signaling and enzyme expression within malignant cells. This tumor exhibits elevated nitric oxide (NO^.) levels. NO^. is a crucial signaling molecule involved in the regulation of neuronal functions, synaptic transmission, and cell proliferation. It is primarily synthesized from L-arginine by nitric oxide synthase (NOS) enzymes. The increased levels of NO^. in GBM stem from dysregulated activity and expression of clinically relevant NOS isoforms, particularly inducible NOS (iNOS) and neuronal NOS (nNOS). Based on this knowledge, we hypothesize that targeted pharmacological intervention with N6-(1-iminoethyl)-L-lysine (L-NIL), an iNOS inhibitor, and 7-Nitroindazole (7-NI), an nNOS inhibitor, may suggest a promising therapeutic strategy for the treatment of GBM. To test our hypothesis, we utilized the U87-MG cell line as an in vitro model of GBM. Our results showed that treatment with L-NIL and 7-NI led to a reduction in NO^. levels, NOS activity, and clonogenic proliferation in U87-MG cells. These findings suggest that NO^. and NOS enzymes might be prospective therapeutic targets for GBM.

Original language	American English
Journal	Journal of Molecular Neuroscience
DOIs	https://doi.org/10.1007/s12031-023-02166-3
State	Accepted/In press - 2023

Bibliographical note

Funding Information:
This work was funded by an Israeli Science Foundation (ISF) grant, an Eagles Autism Foundation grant, a National Institute of Psychobiology in Israel (NIPI) grant, an Israeli Council for Higher Education Maof grant, and a Berettler Centre for Research in Molecular Pharmacology and Therapeutics grant. The authors also thank the Satell Family and the Neubauer Family Foundation.

Funding Information:
The research was partially funded by an American Pharma Company under the terms of a Research and License agreement.

Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Keywords

7-NI
Glioblastoma multiforme
L-NIL
Nitric oxide
Nitric oxide synthase
Treatment

Access to Document

10.1007/s12031-023-02166-3

Cite this

@article{88f48ff202874968b9ea5f2b4d0cdfda,

title = "Nitric Oxide Synthase Inhibition Prevents Cell Proliferation in Glioblastoma",

abstract = "Glioblastoma multiforme (GBM) is a prevalent and aggressive primary brain tumor, presenting substantial treatment challenges and high relapse rates. GBM is characterized by alterations in molecular signaling and enzyme expression within malignant cells. This tumor exhibits elevated nitric oxide (NO.) levels. NO. is a crucial signaling molecule involved in the regulation of neuronal functions, synaptic transmission, and cell proliferation. It is primarily synthesized from L-arginine by nitric oxide synthase (NOS) enzymes. The increased levels of NO. in GBM stem from dysregulated activity and expression of clinically relevant NOS isoforms, particularly inducible NOS (iNOS) and neuronal NOS (nNOS). Based on this knowledge, we hypothesize that targeted pharmacological intervention with N6-(1-iminoethyl)-L-lysine (L-NIL), an iNOS inhibitor, and 7-Nitroindazole (7-NI), an nNOS inhibitor, may suggest a promising therapeutic strategy for the treatment of GBM. To test our hypothesis, we utilized the U87-MG cell line as an in vitro model of GBM. Our results showed that treatment with L-NIL and 7-NI led to a reduction in NO. levels, NOS activity, and clonogenic proliferation in U87-MG cells. These findings suggest that NO. and NOS enzymes might be prospective therapeutic targets for GBM.",

keywords = "7-NI, Glioblastoma multiforme, L-NIL, Nitric oxide, Nitric oxide synthase, Treatment",

author = "Daniel Kruglyakov and Ojha, {Shashank Kumar} and Maryam Kartawy and Tripathi, {Manish Kumar} and Wajeha Hamoudi and Wisam Bazbaz and Igor Khaliulin and Haitham Amal",

note = "Funding Information: This work was funded by an Israeli Science Foundation (ISF) grant, an Eagles Autism Foundation grant, a National Institute of Psychobiology in Israel (NIPI) grant, an Israeli Council for Higher Education Maof grant, and a Berettler Centre for Research in Molecular Pharmacology and Therapeutics grant. The authors also thank the Satell Family and the Neubauer Family Foundation. Funding Information: The research was partially funded by an American Pharma Company under the terms of a Research and License agreement. Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2023",

doi = "10.1007/s12031-023-02166-3",

language = "American English",

journal = "Journal of Molecular Neuroscience",

issn = "0895-8696",

publisher = "Humana Press",

}

TY - JOUR

T1 - Nitric Oxide Synthase Inhibition Prevents Cell Proliferation in Glioblastoma

AU - Kruglyakov, Daniel

AU - Ojha, Shashank Kumar

AU - Kartawy, Maryam

AU - Tripathi, Manish Kumar

AU - Hamoudi, Wajeha

AU - Bazbaz, Wisam

AU - Khaliulin, Igor

AU - Amal, Haitham

N1 - Funding Information: This work was funded by an Israeli Science Foundation (ISF) grant, an Eagles Autism Foundation grant, a National Institute of Psychobiology in Israel (NIPI) grant, an Israeli Council for Higher Education Maof grant, and a Berettler Centre for Research in Molecular Pharmacology and Therapeutics grant. The authors also thank the Satell Family and the Neubauer Family Foundation. Funding Information: The research was partially funded by an American Pharma Company under the terms of a Research and License agreement. Publisher Copyright: © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

PY - 2023

Y1 - 2023

N2 - Glioblastoma multiforme (GBM) is a prevalent and aggressive primary brain tumor, presenting substantial treatment challenges and high relapse rates. GBM is characterized by alterations in molecular signaling and enzyme expression within malignant cells. This tumor exhibits elevated nitric oxide (NO.) levels. NO. is a crucial signaling molecule involved in the regulation of neuronal functions, synaptic transmission, and cell proliferation. It is primarily synthesized from L-arginine by nitric oxide synthase (NOS) enzymes. The increased levels of NO. in GBM stem from dysregulated activity and expression of clinically relevant NOS isoforms, particularly inducible NOS (iNOS) and neuronal NOS (nNOS). Based on this knowledge, we hypothesize that targeted pharmacological intervention with N6-(1-iminoethyl)-L-lysine (L-NIL), an iNOS inhibitor, and 7-Nitroindazole (7-NI), an nNOS inhibitor, may suggest a promising therapeutic strategy for the treatment of GBM. To test our hypothesis, we utilized the U87-MG cell line as an in vitro model of GBM. Our results showed that treatment with L-NIL and 7-NI led to a reduction in NO. levels, NOS activity, and clonogenic proliferation in U87-MG cells. These findings suggest that NO. and NOS enzymes might be prospective therapeutic targets for GBM.

AB - Glioblastoma multiforme (GBM) is a prevalent and aggressive primary brain tumor, presenting substantial treatment challenges and high relapse rates. GBM is characterized by alterations in molecular signaling and enzyme expression within malignant cells. This tumor exhibits elevated nitric oxide (NO.) levels. NO. is a crucial signaling molecule involved in the regulation of neuronal functions, synaptic transmission, and cell proliferation. It is primarily synthesized from L-arginine by nitric oxide synthase (NOS) enzymes. The increased levels of NO. in GBM stem from dysregulated activity and expression of clinically relevant NOS isoforms, particularly inducible NOS (iNOS) and neuronal NOS (nNOS). Based on this knowledge, we hypothesize that targeted pharmacological intervention with N6-(1-iminoethyl)-L-lysine (L-NIL), an iNOS inhibitor, and 7-Nitroindazole (7-NI), an nNOS inhibitor, may suggest a promising therapeutic strategy for the treatment of GBM. To test our hypothesis, we utilized the U87-MG cell line as an in vitro model of GBM. Our results showed that treatment with L-NIL and 7-NI led to a reduction in NO. levels, NOS activity, and clonogenic proliferation in U87-MG cells. These findings suggest that NO. and NOS enzymes might be prospective therapeutic targets for GBM.

KW - 7-NI

KW - Glioblastoma multiforme

KW - L-NIL

KW - Nitric oxide

KW - Nitric oxide synthase

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85174196511&partnerID=8YFLogxK

U2 - 10.1007/s12031-023-02166-3

DO - 10.1007/s12031-023-02166-3

M3 - Article

C2 - 37843719

AN - SCOPUS:85174196511

SN - 0895-8696

JO - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

ER -

Nitric Oxide Synthase Inhibition Prevents Cell Proliferation in Glioblastoma

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this